3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
6
Neoplasms
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Biopsy
4
Nivolumab
3
sodium-iodide symporter
2
fludarabine
2
cemiplimab
2
X-Rays
2
Whole-Body Irradiation
2
Stem Cell Transplantation
2
Photons
2
Mycophenolic Acid
2
Immunoglobulin G
2
Disulfides
2
Cyclosporine
2
treosulfan
1
talimogene laherparepvec
1
ruxolitinib
1
pembrolizumab
1
fludarabine phosphate
1
entrectinib
1
duvelisib
1
alectinib
1
Vinblastine
1
Tacrolimus
1
Standard of Care
1
Sirolimus
1
Practice Guidelines as Topic
1
Peripheral Blood Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
Brentuximab Vedotin
×
30 days
×
Clear all
NCT07013565
2026-05-20
ACCELERATE
New York Medical College
Phase 2
Recruiting
20 enrolled